NCT04146207View on ClinicalTrials.gov

SHR0302 and Steroid As First Line Therapy for Chronic GVHD

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2024

Conditions
Chronic GVHD
Interventions
DRUG

SHR0302

SHR0302 po QD

DRUG

Prednisone

Prednisone 1mg/kg/d po

Trial Locations (2)

200080

Shanghai General Hospital, Shanghai

Xianmin Song, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT04146207 - SHR0302 and Steroid As First Line Therapy for Chronic GVHD | Biotech Hunter | Biotech Hunter